Back to Treatments

Treatment

Ramucirumab + Paclitaxel (Second-line)

1
Conditions
16
Trials
5,000
Participants
30%
Average Safety

Condition Evidence

Stomach cancer

16 trials · 5,000 participants

65% effectiveness · 30% safety
Ramucirumab + Paclitaxel (Second-line) | DFDA